Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jun;29(6):673–684. doi: 10.1111/j.1365-2125.1990.tb03688.x

Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

S W Coppack 1, A F Lant 1, C S McIntosh 1, A V Rodgers 1
PMCID: PMC1380169  PMID: 2116159

Abstract

1. The pharmacokinetic and pharmacodynamic properties of oral glibenclamide have been studied in 31 hospitalised in-patients and 79 ambulant out-patients with diabetes mellitus. 2. Breakfast was found to have no significant influence on the kinetic behaviour of glibenclamide or on the effect of this drug on blood glucose utilisation. 3. The time course of glibenclamide kinetics after 20 mg dosing was adequately described by a two-compartment open model, yielding mean half-lives of 3.3 +/- 1.5 h (t1/2, lambda 1) and 9.7 +/- 1.2 (t1/2, z) for the initial and terminal elimination phases respectively. 4. No significant accumulation or change in kinetic profile occurred in patients who had normal renal and hepatic function, were treated continuously with glibenclamide, and then rechallenged after 8-12 weeks. 5. Despite inter-individual variations in drug absorption, peak plasma concentrations (Cmax) and the area under the plasma concentration-time curve (AUC(0-24] were dose-dependent over the dose range 5-20 mg. No significant dose-response behaviour was observed in respect of glucose utilisation, suggesting that there is little clinical benefit in using doses of glibenclamide above 5 mg day-1. 6. Comparison of plasma glibenclamide concentrations at different time-bands following doses of 5 and 10 mg showed a wider range in ambulant out-patients than in age-, sex-matched in-patients treated with the same dosages of drug. Mean plasma drug concentrations attained at all time bands up to 8 h after dosing were higher in out-patients than in in-patients, suggesting a tendency to 'over-compliance' by patients in anticipation of attendance at clinic.

Full text

PDF
684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams W. J., Skinner G. S., Bombardt P. A., Courtney M., Brewer J. E. Determination of glyburide in human serum by liquid chromatography with fluorescence detection. Anal Chem. 1982 Jul;54(8):1287–1291. doi: 10.1021/ac00245a008. [DOI] [PubMed] [Google Scholar]
  2. Arnqvist H. J., Karlberg B. E., Melander A. Pharmacokinetics and effects of glibenclamide in two formulations, HB 419 and HB 420, in type 2 diabetes. Ann Clin Res. 1983;15 (Suppl 37):21–25. [PubMed] [Google Scholar]
  3. Asplund K., Wiholm B. E., Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 1983 Jun;24(6):412–417. doi: 10.1007/BF00257338. [DOI] [PubMed] [Google Scholar]
  4. Ayanoglu G., Witte P. U., Badian M. Bioavailability and pharmacodynamics of a sustained-release glibenclamide product (Deroctyl) in comparison to a standard tablet formulation (Euglucon, Daonil). Int J Clin Pharmacol Ther Toxicol. 1983 Sep;21(9):479–482. [PubMed] [Google Scholar]
  5. Balant L., Fabre J., Zahnd G. R. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol. 1975;8(1):63–69. doi: 10.1007/BF00616416. [DOI] [PubMed] [Google Scholar]
  6. Balant L., Zahnd G. R., Weber F., Fabre J. Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol. 1977;11(1):19–25. doi: 10.1007/BF00561783. [DOI] [PubMed] [Google Scholar]
  7. Castoldi D., Tofanetti O. Gas chromatographic determination of glibenclamide in plasma. Clin Chim Acta. 1979 Apr 16;93(2):195–198. doi: 10.1016/0009-8981(79)90088-3. [DOI] [PubMed] [Google Scholar]
  8. Chalk J. B., Patterson M., Smith M. T., Eadie M. J. Correlations between in vitro dissolution, in vivo bioavailability and hypoglycaemic effect of oral glibenclamide. Eur J Clin Pharmacol. 1986;31(2):177–182. doi: 10.1007/BF00606655. [DOI] [PubMed] [Google Scholar]
  9. Feldman J. M. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy. 1985 Mar-Apr;5(2):43–62. doi: 10.1002/j.1875-9114.1985.tb03404.x. [DOI] [PubMed] [Google Scholar]
  10. Ferner R. E., Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet. 1987 Jun;12(6):379–401. doi: 10.2165/00003088-198712060-00001. [DOI] [PubMed] [Google Scholar]
  11. George C. F. Food, drugs, and bioavailability. Br Med J (Clin Res Ed) 1984 Oct 27;289(6452):1093–1094. doi: 10.1136/bmj.289.6452.1093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Huupponen R., Viikari J., Saarimaa H. Chlorpropamide and glibenclamide serum concentrations in hospitalized patients. Ann Clin Res. 1982 Jun;14(3):119–122. [PubMed] [Google Scholar]
  13. Ikegami H., Shima K., Tanaka A., Tahara Y., Hirota M., Kumahara Y. Interindividual variation in the absorption of glibenclamide in man. Acta Endocrinol (Copenh) 1986 Apr;111(4):528–532. doi: 10.1530/acta.0.1110528. [DOI] [PubMed] [Google Scholar]
  14. Johnston A., Woollard R. C. STRIPE: an interactive computer program for the analysis of drug pharmacokinetics. J Pharmacol Methods. 1983 May;9(3):193–199. doi: 10.1016/0160-5402(83)90038-4. [DOI] [PubMed] [Google Scholar]
  15. Kawashima K., Kuzuya T., Matsuda A. Radioimmunoassay of glibenclamide. Diabetes. 1979 Mar;28(3):221–226. doi: 10.2337/diab.28.3.221. [DOI] [PubMed] [Google Scholar]
  16. Kobayashi K., Kimura M., Sakoguchi T., Hase A., Matsuoka A., Kaneko S. Pharmacokinetics of gliclazide in healthy and diabetic subjects. J Pharm Sci. 1984 Dec;73(12):1684–1687. doi: 10.1002/jps.2600731204. [DOI] [PubMed] [Google Scholar]
  17. Marchetti P., Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet. 1989 Feb;16(2):100–128. doi: 10.2165/00003088-198916020-00004. [DOI] [PubMed] [Google Scholar]
  18. Matsuda A., Kuzuya T., Sugita Y., Kawashima K. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res. 1983 Sep;15(9):425–428. doi: 10.1055/s-2007-1018746. [DOI] [PubMed] [Google Scholar]
  19. Melander A., Sartor G., Wåhlin E., Scherstén B., Bitzén P. O. Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus. Br Med J. 1978 Jan 21;1(6106):142–144. doi: 10.1136/bmj.1.6106.142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nattrass M. Treatment of type II diabetes. Br Med J (Clin Res Ed) 1986 Apr 19;292(6527):1033–1034. doi: 10.1136/bmj.292.6527.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Neugebauer G., Betzien G., Hrstka V., Kaufmann B., von Möllendorff E., Abshagen U. Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). Int J Clin Pharmacol Ther Toxicol. 1985 Sep;23(9):453–460. [PubMed] [Google Scholar]
  22. Osborn M., Hawton K., Gath D. Sexual dysfunction among middle aged women in the community. Br Med J (Clin Res Ed) 1988 Apr 2;296(6627):959–962. doi: 10.1136/bmj.296.6627.959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pearson J. G., Antal E. J., Raehl C. L., Gorsch H. K., Craig W. A., Albert K. S., Welling P. G. Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther. 1986 Mar;39(3):318–324. doi: 10.1038/clpt.1986.46. [DOI] [PubMed] [Google Scholar]
  24. Pearson J. G. Pharmacokinetics of glyburide. Am J Med. 1985 Sep 20;79(3B):67–71. doi: 10.1016/s0002-9343(85)80010-3. [DOI] [PubMed] [Google Scholar]
  25. Peart G. F., Boutagy J., Shenfield G. M. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clin Pharmacol Ther. 1989 Mar;45(3):277–284. doi: 10.1038/clpt.1989.28. [DOI] [PubMed] [Google Scholar]
  26. Prendergast B. D. Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm. 1984 Sep-Oct;3(5):473–485. [PubMed] [Google Scholar]
  27. Rogers H. J., Spector R. G., Morrison P. J., Bradbrook I. D. Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. Diabetologia. 1982 Jul;23(1):37–40. doi: 10.1007/BF00257728. [DOI] [PubMed] [Google Scholar]
  28. Rupp W., Christ O., Fülberth W. Untersuchungen zur Bioavailability von Glibenclamid. Arzneimittelforschung. 1972 Feb;22(2):471–473. [PubMed] [Google Scholar]
  29. Ryan D. W., Oyston J. Sulphonylureas and hypoglycaemia. Br Med J (Clin Res Ed) 1988 May 7;296(6632):1328–1328. doi: 10.1136/bmj.296.6632.1328-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Samanta A., Jones G. R., Burden A. C., Shakir I. Improved effect of tolbutamide when given before food in patients on long-term therapy. Br J Clin Pharmacol. 1984 Oct;18(4):647–648. doi: 10.1111/j.1365-2125.1984.tb02522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sartor G., Lundquist I., Melander A., Scherstén B., Wåhlin-Boll E. Improved effect of glibenclamide on administration before breakfast. Eur J Clin Pharmacol. 1982;21(5):403–408. doi: 10.1007/BF00542327. [DOI] [PubMed] [Google Scholar]
  32. Sartor G., Melander A., Scherstén B., Wåhlin-Boll E. Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers. Acta Med Scand. 1980;208(4):301–307. doi: 10.1111/j.0954-6820.1980.tb01199.x. [DOI] [PubMed] [Google Scholar]
  33. Sartor G., Melander A., Scherstén B., Wåhlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia. 1980 Jan;18(1):17–22. doi: 10.1007/BF01228296. [DOI] [PubMed] [Google Scholar]
  34. Semple C. G., Omile C., Buchanan K. D., Beastall G. H., Paterson K. R. Effect of oral verapamil on glibenclamide stimulated insulin secretion. Br J Clin Pharmacol. 1986 Aug;22(2):187–190. doi: 10.1111/j.1365-2125.1986.tb05248.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Sjöberg S., Wiholm B. E., Gunnarsson R., Emilsson H., Thunberg E., Christenson I., Ostman J. Lack of pharmacokinetic interaction between glibenclamide and trimethoprim-sulphamethoxazole. Diabet Med. 1987 May-Jun;4(3):245–247. doi: 10.1111/j.1464-5491.1987.tb00872.x. [DOI] [PubMed] [Google Scholar]
  36. Swift C. G., McLaren S., MacLean D., Stevenson I. H. Plasma concentrations of oral hypoglycaemic drugs in diabetic clinic patients [proceedings]. Br J Clin Pharmacol. 1979 Oct;8(4):406P–407P. [PubMed] [Google Scholar]
  37. Uihlein M., Sistovaris N. High-performance liquid column and thin-layer chromatographic determination of human serum glibenclamide at therapeutic levels. J Chromatogr. 1982 Jan 8;227(1):93–101. doi: 10.1016/s0378-4347(00)80359-x. [DOI] [PubMed] [Google Scholar]
  38. Welling P. G. Interactions affecting drug absorption. Clin Pharmacokinet. 1984 Sep-Oct;9(5):404–434. doi: 10.2165/00003088-198409050-00002. [DOI] [PubMed] [Google Scholar]
  39. Winstanley P. A., Orme M. L. The effects of food on drug bioavailability. Br J Clin Pharmacol. 1989 Dec;28(6):621–628. doi: 10.1111/j.1365-2125.1989.tb03554.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wåhlin-Boll E., Melander A. High-performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum. J Chromatogr. 1979 Dec 1;164(4):541–546. doi: 10.1016/s0378-4347(00)81560-1. [DOI] [PubMed] [Google Scholar]
  41. Wåhlin-Boll E., Sartor G., Melander A., Scherstén B. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol. 1982;22(1):21–25. doi: 10.1007/BF00606420. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES